All In Biotech

Drug Trial Radar · NCT00131144

Octreotide Acetate in Microspheres in Patients With Diabetic Retinopathy

A Randomized, Controlled Study on the Efficacy and Safety of Octreotide Acetate in Microspheres in the Therapy of Patients With Moderately Severe or Severe Non-proliferate Diabetic Retinopathy (NPDR) or Low Risk Proliferative Diabetic Retinopathy (PDR)

Last checked: Nov 19, 2026Latest source record: Nov 17, 2011 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 583 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

583

Actual

Start

Nov 1999

Primary completion

Dec 2005

Study completion Dec 2005

Sponsor

Lead sponsor
NovartisNovartis (NVS)
Sponsor type
Industry
First posted
Aug 17, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The most common ocular disease in patients with diabetes, diabetic retinopathy, is present in approximately 40% of diabetic patients; about 8% of diabetic patients have vision threatening diabetic retinopathy. Although intensive control of blood glucose has been shown to reduce the development and progression of diabetic retinopathy, intensive control of glucose is usually not achieved in clinical practice.

Conditions

  • Diabetic Retinopathy

Interventions

  • Octreotide Acetate in Microspheres 20 mgDrug

  • Octreotide Acetate in MicrospheresDrug

  • PlaceboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. time to progression of diabetic retinopathyTime frame: throughout study

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Novartis

    East Hanover, New Jersey

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.